"Poland Pharmaceuticals & Healthcare Report Q1 2011" now available at Fast Market Research

Nov. 25, 2010 - PRLog -- Poland is an important pharmaceutical market in Central and Eastern Europe (CEE), and is a relatively well-developed market compared with those to the east. Poland's total drug expenditure and projected growth rates are below Russia and Turkey's respective figures. However, Poland's considerably more favourable business environment makes it a more attractive investment opportunity, which is illustrated in BMI's latest Pharmaceuticals and Healthcare Business Environment Ratings (BERs) index.

Poland remains in second place in CEE for Q111, with an overall score of 62.5. A strong performance in 2009 and significant growth projected for 2010 & 2011 benefit the high Industry Rewards score. The BER score has edged above the Q410 figure as a result of an improved Country Risk outlook.

BMI forecasts that Poland's pharmaceutical market will increase from PLN30.25bn (US$10.56bn) in 2009 to PLN32.23bn (US$11.13bn) in 2010. Between 2009 and 2014, BMI projects a compound annual growth rate (CAGR) of 7.04% in local currency terms and 8.80% in US dollar terms.

A multinational survey in 2010 has revealed that Poland is considered to have one of the worst healthcare systems in Europe and that public opinion is split on how to resolve the issue. The Polish respondents identified a lack of public funding as the most significant upcoming threat to their healthcare system. A total of 30% of respondents favoured increasing private insurance, optional supplemental insurance or supplemental policies from mutual insurance companies, while 28% preferred increased taxes or compulsory contributions.

On October 10 2010, the Ministry of Health submitted the latest draft act on the reimbursement of medicines, which is one of the most significant components of the healthcare reform. The draft legislation includes a fixed wholesale mark-up of 5% on reimbursed prescription drugs. The method for establishing reference drugs for reimbursement calculations is also to be changed. The existing reimbursement categories are to be maintained but with more precise criteria. The draft bill states that 17% of the total annual budget of the Polish National Health Fund (NFZ) is to be spent on the reimbursement of medicines. In addition, the legislation includes regulation for the establishment of formal risk-sharing agreements, associated with the proposed increase in NFZ spending.

Poland's macroeconomic economic outlook is encouraging. BMI reiterates our long-held view that Poland will prove a growth outperformer over the short and long term, as the nation's domestic demand base shields the economy from the worst of the global headwinds, while economic convergence with Western Europe propels higher living standards.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/94402_poland_pharmaceuticals_h...

Report Table of Contents:

Executive Summary
SWOT Analysis
- Poland Pharmaceuticals Industry SWOT
- Poland Political SWOT
- Poland Economic SWOT
- Poland Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Emerging Europe - Regional Pharmaceutical Business Environment Ratings, Q111
- Rewards
- Risks
Poland - Market Summary
Regulatory Regime
- Intellectual Property Developments
- Pricing And Reimbursement Regime
- Pricing Policies
- Reimbursement Policies
- Recent Developments in Reimbursement System
- Marketing Regulations
- Other Regulatory Developments
Industry Trends and Developments
- Epidemiology
- Table: Disease Burden In CEE
- Healthcare System
- Healthcare Funding
- Healthcare Reforms
- Health Insurance
- Research And Development
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2006-2014
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2006 -2014
- Table: Government Healthcare Expenditure Indicators 2006 -2014
- Table: Private Healthcare Expenditure Indicators 2006 -2014
- Key Growth Factors - Macroeconomic
- Table: Poland - GDP By Expenditure
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2006-2014
- Patented Product Market Forecast
- Table: Patented Drug Market Indicators 2006-2014
- Generic Drug Market Forecast
- Table: Generic DrugSales Indicators 2006-2014
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2006-2014
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Export & Import Indicators 2006-2014
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2006-2014
- Other Healthcare Data Forecasts
- Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Domestic Industry
- Domestic Company Developments
- Foreign Industry
- Foreign Company Developments
- Biotechnology Sector
- Pharmaceutical Wholesale Sector
- Pharmaceutical Retail Sector
- Table: Poland's Pharmacies & Pharmacy Market Ratios, 2004-2009
Company Profiles
- Polpharma
- Bioton
- GlaxoSmithKline
- Eli Lilly
- Gedeon Richter
- Krka
- Lek
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.